Granted Patent
B2
US 12,533,411 · App. 17/324,478 · Granted Jan 27, 2026
Compositions comprising anti-CD38 antibodies and carfilzomib
Inventors:
Blake Tomkinson (Bridgewater, NJ); Blake T. Aftab (San Francisco, CA); Byron C. Hann (San Francisco, CA); Thomas G. Martin, III (San Francisco, CA)
A61K39/39533A61K9/0019A61K9/0053A61K31/573A61K38/07A61K38/08A61K39/39558C07K16/2896C07K16/3061A61K2039/505A61K2039/54A61K2039/545C07K2317/24C07K2317/56C07K2317/73C07K2317/732C07K2317/734
View Patent ↗
Loading inventors, assignments & file history…
Abstract
Disclosed herein are compositions and kits which comprise anti-CD38 antibodies and carfilzomib compounds. Also disclosed are methods for treating cancers, such as multiple myeloma, in subjects with the compositions and kits.
Claims (12)
1 . A method of treating multiple myeloma in a subject comprising administering an anti-CD38 antibody and carfilzomib to the subject, wherein the anti-CD38 antibody comprises a heavy chain having a VH variable region comprising an amino acid sequence set forth in SEQ ID NO: 66, and a light chain having a V L variable region comprising an amino acid sequence set forth in either SEQ ID NO: 62 or SEQ ID NO: 64;
wherein the subject has undergone at least two prior therapies for multiple myeloma, and
wherein the anti-CD38 antibody and carfilzomib are administered in a synergistic amount.
2 . The method of claim 1 , wherein the multiple myeloma is a relapsed multiple myeloma or a refractory multiple myeloma.
3 . The method of claim 1 , wherein the anti-CD38 antibody and carfilzomib are administered in a therapeutically effective amount.
4 . The method of claim 1 , wherein the anti-CD38 antibody is capable of killing a CD38 + cell by apoptosis, antibody-dependent cell-mediated cytotoxicity (ADCC), and complement-dependent cytotoxicity (CDC).
5 . The method of claim 1 , wherein the anti-CD38 antibody is administered intravenously.
6 . The method of claim 1 , wherein carfilzomib is administered intravenously.
7 . The method of claim 1 , wherein the anti-CD38 antibody and carfilzomib are administered sequentially.
8 . The method of claim 1 , further comprising administering dexamethasone to the subject.
9 . The method of claim 8 , wherein dexamethasone is administered orally.
10 . The method of claim 8 , wherein the anti-CD38 antibody, carfilzomib, and dexamethasone are administered sequentially.
Assignments (3)
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jul 20, 2022
From: SANOFI
To: SANOFI-AVENTIS U.S. LLC
Reel/Frame 060757/0518 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 7, 2021
From: TOMKINSON, BLAKE
To: SANOFI
Reel/Frame 056460/0085 →
ASSIGNMENT OF ASSIGNOR'S INTEREST
Recorded Jun 7, 2021
From: HANN, BYRON C.; MARTIN, THOMAS G., III; AFTAB, BLAKE T.
To: THE REGENTS OF THE UNIVERSITY OF CALIFORNIA
Reel/Frame 056460/0093 →
Continuity (6)
Continuation
14775641
Provisional Application
61808381
· Apr 4, 2013
Provisional Application
61778540
· Mar 13, 2013
References Cited (121)
US 4444887A
· Hoffmann
· 1984
[cited by applicant]
US 4716111A
· Osband et al.
· 1987
[cited by applicant]
US 4816397A
· Boss et al.
· 1989
[cited by applicant]
US 4816567A
· Cabilly et al.
· 1989
[cited by applicant]
US 5530101A
· Queen et al.
· 1996
[cited by applicant]
US 5545806A
· Lonberg et al.
· 1996
[cited by applicant]
US 5565332A
· Hoogenboom et al.
· 1996
[cited by applicant]
US 5585089A
· Queen et al.
· 1996
[cited by applicant]
US 5639641A
· Pedersen et al.
· 1997
[cited by applicant]
US 5807715A
· Morrison et al.
· 1998
[cited by applicant]
US 5814318A
· Lonberg et al.
· 1998
[cited by applicant]
US 7232818B2
· Smyth et al.
· 2007
[cited by applicant]
US 7417042B2
· Smyth et al.
· 2008
[cited by applicant]
US 7491704B2
· Smyth et al.
· 2009
[cited by applicant]
US 7737112B2
· Lewis et al.
· 2010
[cited by applicant]
US 8129346B2
· Smyth et al.
· 2012
[cited by applicant]
US 8153765B2
· Park
· 2012
[cited by applicant]
US 8207125B2
· Smyth et al.
· 2012
[cited by applicant]
US 8207126B2
· Smyth et al.
· 2012
[cited by applicant]
US 8207127B2
· Smyth et al.
· 2012
[cited by applicant]
US 8207297B2
· Smyth et al.
· 2012
[cited by applicant]
US 8491898B2
· Cardarelli et al.
· 2013
[cited by applicant]
US 20090270419A1
· Arts et al.
· 2009
[cited by applicant]
US 20090304710A1
· Park
· 2009
[cited by applicant]
US 20100028346A1
· Lutz et al.
· 2010
[cited by applicant]
US 20100092489A1
· Van De Winkel et al.
· 2010
[cited by applicant]
US 20110123554A1
· Osterroth et al.
· 2011
[cited by applicant]
US 20110262454A1
· Park et al.
· 2011
[cited by applicant]
US 20120082670A1
· Konopitzky et al.
· 2012
[cited by applicant]
US 20120156218A1
· Park et al.
· 2012
[cited by applicant]
US 20140161819A1
· Hann et al.
· 2014
[cited by applicant]
US 20150118251A1
· Deslandes et al.
· 2015
[cited by applicant]
US 20160022813A1
· Tomkinson
· 2016
[cited by applicant]
US 20170106085A1
· Tomkinson
· 2017
[cited by applicant]
US 20170343550A1
· Park et al.
· 2017
[cited by applicant]
US 20180022814A1
· Deslandes et al.
· 2018
[cited by applicant]
US 20190284294A1
· Deslandes et al.
· 2019
[cited by applicant]
US 20190321471A1
· Tomkinson
· 2019
[cited by applicant]
US 20200046832A1
· Hann et al.
· 2020
[cited by applicant]
US 20200239589A1
· Audat
· 2020
[cited by applicant]
US 20200408765A1
· Park et al.
· 2020
[cited by applicant]
US 20220135696A1
· Semiond et al.
· 2022
[cited by applicant]
US 20240190984A1
· Audat et al.
· 2024
[cited by applicant]
US 20250177519A1
· Chiron Blondel et al.
· 2025
[cited by applicant]
US 20250216392A1
· Park et al.
· 2025
[cited by applicant]
CN 101534860A
· 2009
[cited by applicant]
CN 101616933A
· 2009
[cited by applicant]
CN 102065891A
· 2011
[cited by applicant]
CN 102264386A
· 2011
[cited by applicant]
CN 102573916A
· 2012
[cited by applicant]
EP 0239400A2
· 1987
[cited by applicant]
EP 0519596A1
· 1992
[cited by applicant]
EP 0592106A1
· 1994
[cited by applicant]
EP 1914242A1
· 2008
[cited by applicant]
JP 2010506582A
· 2010
[cited by applicant]
JP 2012506445A
· 2012
[cited by applicant]
RU 2006132045A
· 2008
[cited by applicant]
RU 2007134661A
· 2009
[cited by applicant]
RU 2425841C2
· 2011
[cited by applicant]
RU 2456990C2
· 2012
[cited by applicant]
WO WO199109967A1
· 1991
[cited by applicant]
WO WO199110741A1
· 1991
[cited by applicant]
WO WO199222653A1
· 1992
[cited by applicant]
WO WO199633735A1
· 1996
[cited by applicant]
WO WO199634096A1
· 1996
[cited by applicant]
WO WO199816654A1
· 1998
[cited by applicant]
WO WO199824893A2
· 1998
[cited by applicant]
WO WO199824893A3
· 1998
[cited by applicant]
WO WO199846645A2
· 1998
[cited by applicant]
WO WO199846645A3
· 1998
[cited by applicant]
WO WO199850433A2
· 1998
[cited by applicant]
WO WO199850433A3
· 1998
[cited by applicant]
WO WO2006088951A2
· 2006
[cited by applicant]
WO WO2008047242A2
· 2008
[cited by applicant]
WO WO2008047242A3
· 2008
[cited by applicant]
WO WO2009032661A1
· 2009
[cited by applicant]
WO WO2010048298A1
· 2010
[cited by applicant]
WO WO2010057048A1
· 2010
[cited by applicant]
WO WO2010061359A1
· 2010
[cited by applicant]
WO WO2012041800A1
· 2012
[cited by applicant]
WO WO2012066058A1
· 2012
[cited by applicant]
WO WO2012076663A1
· 2012
[cited by applicant]
WO WO2012135528A2
· 2012
[cited by applicant]
McCormack (Drugs. Oct. 22, 2012; 72(15):2023-32) (Year: 2012).
[cited by examiner]
Bataille, R. et al. (Sep. 2006). “The Phenotype of Normal, Reactive and Malignant Plasma Cells. Identification of “Many and Multiple Myelomas” and of New Targets for Myeloma Therapy,”
[cited by applicant]
De Weers et al. (Feb. 1, 2011). “Daratumumab, a Novel Therapeutic Human CD38. Monoclonal Antibody, Induces Killing of Multiple Myeloma and Other Hematological Tumors,”
[cited by applicant]
Dimopoulos, M.A. et al. (Jul. 2010). “Lenalidomide and Dexamethasone for the Treatment of Refractory/Relapsed Multiple Myeloma: Dosing of Lenalidomide According to Renal Function and Effect on Renal Impairment,”
[cited by applicant]
European communication Pursuant to Article 94(3) EPC mailed on Oct. 9, 2017, for EP Application No. 14773270.5 filed on Mar. 13, 2014, four pages.
[cited by applicant]
European communication Pursuant to Rules 70(2) and 70a(2) EPC mailed Oct. 5, 2016 for EP Application No. 14773270.5 filed on Mar. 13, 2014, one page.
[cited by applicant]
Extended European Search Report mailed Sep. 16, 2016 for EP Application No. 14773270.5 filed on Mar. 13, 2014, eight pages.
[cited by applicant]
Gillies, S.D. et al. (Dec. 20, 1989). “High-Level Expression of Chimeric Antibodies Using Adapted cDNA Variable Region Cassettes,”
[cited by applicant]
International Search Report mailed on Jul. 24, 2014, for PCT Patent Application No. PCT/US2014/025441, filed on Mar. 13, 2014, five pages.
[cited by applicant]
Kim, D. et al. (Dec. 2012). “CD19
[cited by applicant]
Kurtin, S.E. (Nov./Dec. 2013). “Relapsed or Relapsed/Refractory Multiple Myelome,”
[cited by applicant]
Liu, N. et al. (Jan. 2013). “Novel Agents for Relapsed/Refractory Multiple Myeloma,”
[cited by applicant]
Martin, T.G. et al. (Dec. 3-6, 2016). “2111 Phase 1b Study of Isatuximab and Carfilzomib in Relapse and Refractory Multiple Myeloma,” presented at
[cited by applicant]
Moreau, P. et al. (2020, e-pub Dec. 13, 2019). “Isatuximab Plus Carfilzomib And Dexamethasone Vs Carfilzomib And Dexamethasone In Relapsed/Refractory Multiple Myeloma: IKEMA Phase III Study Design,” Future Oncology 4347…
[cited by applicant]
Morrison, S.L. (Sep. 20, 1985). “Transfectomas Provide Novel Chimeric Antibodies,”
[cited by applicant]
Oi, V.T. et al. (1986). “Chimeric Antibodies,”
[cited by applicant]
Padlan, E.A. (Apr.-May 1991). “A Possible Procedure for Reducing the Immunogenicity of Antibody Variable Domains While Preserving Their Ligand-Binding Properties,”
[cited by applicant]
Rajkumar, S.V. et al. (2011). “Consensus Recommendations For The Uniform Reporting Of Clinical Trials: Report Of The International Myelomaworkshop Consensus Panel 1,”
[cited by applicant]
Richardson, P.G. et al., (2011) “Monoclonal Antibodies in the Treatment of Multiple Myeloma,”
[cited by applicant]
Roguska, M.A. et al. (Feb. 1, 1994). “Humanization of Murine Monoclonal Antibodies Through Variable Domain Resurfacing,”
[cited by applicant]
Studnicka, G.M. et al. (Jun. 1994). “Human-Engineered Monoclonal Antibodies Retain Full Specific Binding Activity by Preserving Non-CDR Complementarity-Modulating Residues,”
[cited by applicant]
Van Der Veer, M.S. et al. (Feb. 2011). “Towards Effective Immunotherapy of Myeloma: Enhanced Elimination of Myeloma Cells by Combination of Lenalidomide with the Human CD38 Monoclonal Antibody Daratumumab,”
[cited by applicant]
Wang, et al. (2011) Abstract #8025, 2011 ASCO Annual Meeting,
[cited by applicant]
Wang, H. et al. (Mar. 1, 2004). “Pretreatment with Dexamethasone Increases Antitumor Activity of Carboplatin and Gemcitabine in Mice Bearing Human Cancer Xenografts,”
[cited by applicant]
Wetzel, M-C. et al. (Apr. 15, 2013). “Abstract 4735: SAR650984: Characterization of a Potent Phase I Humanized Anti-CD38 Antibody for the Treatment of Multiple Myeloma and Other Hematologic Malignancies,” Proceedings: A…
[cited by applicant]
Yang, S. et al. (2004). “Expression of Leucocyte Cell-Surface Antigens on Colon Cancer Cell Line HR8348,”
[cited by applicant]
Kuhn, D.J. et al. (Nov. 1, 2007). “Potent Activity Of Carfilzomib, A Novel, Irreversible Inhibitor Of The Ubiquitin-Proteasome Pathway, Against Preclinical Models Of Multiple Myeloma,” Blood 110(9):3281-3290.
[cited by applicant]
Schots, R. et al. (Apr. 30, 2011). “Recent Advances In Myeloma Treatment,” Transfusion and Apheresis Science 44 (2):223-229.
[cited by applicant]
Zhang, Y.C. editor (2011). Immune Disease, pp. 646, total 5 pages with English Translation.
[cited by applicant]
U.S. Appl. No. 14/687,179, filed Apr. 15, 2015, for Peter U. U. Park et al.
[cited by applicant]
U.S. Appl. No. 15/931,466, filed May 13, 2020, for Heloise Audat et al.
[cited by applicant]
U.S. Appl. No. 16/249,538, filed Jan. 16, 2019, for Peter U. U. Park et al.
[cited by applicant]
U.S. Appl. No. 16/526,969, filed Jul. 30, 2019, for Peter U. U. Park et al.
[cited by applicant]
U.S. Appl. No. 17/112,862, filed Dec. 4, 2020, for Marie-Laure Risse et al.
[cited by applicant]
U.S. Appl. No. 18/391,403, filed Dec. 20, 2023, for Peter U. U. Park et al.
[cited by applicant]